-
1
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
-
(2014)
CA Cancer J Clin
, vol.64
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
2
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
-
3
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25: 1539-1544.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
O'Dwyer, P.J.4
Mitchell, E.P.5
Alberts, S.R.6
Schwartz, M.A.7
Benson, A.B.8
-
4
-
-
84867047384
-
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
-
Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30: 3499-3506.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3499-3506
-
-
Van Cutsem, E.1
Tabernero, J.2
Lakomy, R.3
Prenen, H.4
Prausova, J.5
Macarulla, T.6
Ruff, P.7
van Hazel, G.A.8
Moiseyenko, V.9
Ferry, D.10
McKendrick, J.11
Polikoff, J.12
Tellier, A.13
-
5
-
-
84872921660
-
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
-
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381: 303-312.
-
(2013)
Lancet
, vol.381
, pp. 303-312
-
-
Grothey, A.1
Van Cutsem, E.2
Sobrero, A.3
Siena, S.4
Falcone, A.5
Ychou, M.6
Humblet, Y.7
Bouche, O.8
Mineur, L.9
Barone, C.10
Adenis, A.11
Tabernero, J.12
Yoshino, T.13
-
6
-
-
84871879404
-
Antiangiogenesis therapy in the treatment of metastatic colorectal cancer
-
Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012; 4: 301-319.
-
(2012)
Ther Adv Med Oncol
, vol.4
, pp. 301-319
-
-
Grothey, A.1
Allegra, C.2
-
7
-
-
20544455330
-
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
-
Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005; 333: 328-335.
-
(2005)
Biochem Biophys Res Commun
, vol.333
, pp. 328-335
-
-
Ferrara, N.1
Hillan, K.J.2
Novotny, W.3
-
8
-
-
65349186800
-
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
-
Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther. 2009; 9: 263-271.
-
(2009)
Expert Opin Biol Ther
, vol.9
, pp. 263-271
-
-
Chu, Q.S.1
-
9
-
-
79954499886
-
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
-
Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011; 129: 245-255.
-
(2011)
Int J Cancer
, vol.129
, pp. 245-255
-
-
Wilhelm, S.M.1
Dumas, J.2
Adnane, L.3
Lynch, M.4
Carter, C.A.5
Schutz, G.6
Thierauch, K.H.7
Zopf, D.8
-
10
-
-
77956083776
-
Treatment of colorectal cancer with and without bevacizumab: a phase III study
-
Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios S, Stathopoulos J, Legakis J, Armakolas A. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology. 2010; 78: 376-381.
-
(2010)
Oncology
, vol.78
, pp. 376-381
-
-
Stathopoulos, G.P.1
Batziou, C.2
Trafalis, D.3
Koutantos, J.4
Batzios, S.5
Stathopoulos, J.6
Legakis, J.7
Armakolas, A.8
-
11
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study
-
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26: 2013-2019.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Diaz-Rubio, E.3
Scheithauer, W.4
Figer, A.5
Wong, R.6
Koski, S.7
Lichinitser, M.8
Yang, T.S.9
Rivera, F.10
Couture, F.11
Sirzen, F.12
Cassidy, J.13
-
12
-
-
84938095204
-
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial
-
Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, Ruscelli S, Mucciarini C, Lorusso V, Ragazzini A, Frassineti GL, Amadori D. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol. 2015; 26: 1201-1207.
-
(2015)
Ann Oncol
, vol.26
, pp. 1201-1207
-
-
Passardi, A.1
Nanni, O.2
Tassinari, D.3
Turci, D.4
Cavanna, L.5
Fontana, A.6
Ruscelli, S.7
Mucciarini, C.8
Lorusso, V.9
Ragazzini, A.10
Frassineti, G.L.11
Amadori, D.12
-
13
-
-
0037208589
-
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
-
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21: 60-65.
-
(2003)
J Clin Oncol
, vol.21
, pp. 60-65
-
-
Kabbinavar, F.1
Hurwitz, H.I.2
Fehrenbacher, L.3
Meropol, N.J.4
Novotny, W.F.5
Lieberman, G.6
Griffing, S.7
Bergsland, E.8
-
14
-
-
20544478429
-
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial
-
Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23: 3697-3705.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3697-3705
-
-
Kabbinavar, F.F.1
Schulz, J.2
McCleod, M.3
Patel, T.4
Hamm, J.T.5
Hecht, J.R.6
Mass, R.7
Perrou, B.8
Nelson, B.9
Novotny, W.F.10
-
15
-
-
77955497309
-
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
-
Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010; 28: 3191-3198.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3191-3198
-
-
Tebbutt, N.C.1
Wilson, K.2
Gebski, V.J.3
Cummins, M.M.4
Zannino, D.5
van Hazel, G.A.6
Robinson, B.7
Broad, A.8
Ganju, V.9
Ackland, S.P.10
Forgeson, G.11
Cunningham, D.12
Saunders, M.P.13
-
16
-
-
84884700039
-
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
-
Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP, AVEX study investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14: 1077-1085.
-
(2013)
Lancet Oncol
, vol.14
, pp. 1077-1085
-
-
Cunningham, D.1
Lang, I.2
Marcuello, E.3
Lorusso, V.4
Ocvirk, J.5
Shin, D.B.6
Jonker, D.7
Osborne, S.8
Andre, N.9
Waterkamp, D.10
Saunders, M.P.11
-
17
-
-
84908573757
-
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
-
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15: 1065-1075.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1065-1075
-
-
Heinemann, V.1
von Weikersthal, L.F.2
Decker, T.3
Kiani, A.4
Vehling-Kaiser, U.5
Al-Batran, S.E.6
Heintges, T.7
Lerchenmuller, C.8
Kahl, C.9
Seipelt, G.10
Kullmann, F.11
Stauch, M.12
Scheithauer, W.13
-
18
-
-
84923199426
-
Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS valuable population
-
Stintzing S, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Scheithauer W, et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS valuable population. Ann Oncol. 2014; 25: 1.
-
(2014)
Ann Oncol
, vol.25
, pp. 1
-
-
Stintzing, S.1
Modest, D.P.2
Fischer von Weikersthal, L.3
Decker, T.4
Kiani, A.5
Vehling-Kaiser, U.6
Al-Batran, S.7
Heintges, T.8
Lerchenmueller, C.9
Kahl, C.10
Seipelt, G.11
Kullmann, F.12
Scheithauer, W.13
-
19
-
-
84937204003
-
CALGB/ SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
-
Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony MR, O'Neil BH, Shaw JE, Polite B, Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky RL, et al. CALGB/ SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Ann Oncol. 2014; 25 (suppl 4).
-
(2014)
Ann Oncol
, vol.25
-
-
Lenz, H.1
Niedzwiecki, D.2
Innocenti, F.3
Blanke, C.4
Mahony, M.R.5
O'Neil, B.H.6
Shaw, J.E.7
Polite, B.8
Hochster, H.9
Atkins, J.10
Goldberg, R.11
Mayer, R.12
Schilsky, R.L.13
-
20
-
-
84929519878
-
Role of First-Line Anti-Epidermal Growth Factor Receptor Therapy Compared With Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials
-
Khattak MA, Martin H, Davidson A, Phillips M. Role of First-Line Anti-Epidermal Growth Factor Receptor Therapy Compared With Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials. Clin Colorectal Cancer. 2015; 14:81-90.
-
(2015)
Clin Colorectal Cancer
, vol.14
, pp. 81-90
-
-
Khattak, M.A.1
Martin, H.2
Davidson, A.3
Phillips, M.4
-
21
-
-
84953856186
-
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
-
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16: 1306-1315.
-
(2015)
Lancet Oncol
, vol.16
, pp. 1306-1315
-
-
Cremolini, C.1
Loupakis, F.2
Antoniotti, C.3
Lupi, C.4
Sensi, E.5
Lonardi, S.6
Mezi, S.7
Tomasello, G.8
Ronzoni, M.9
Zaniboni, A.10
Tonini, G.11
Carlomagno, C.12
Allegrini, G.13
-
22
-
-
84871720057
-
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
-
Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, Steffens CC, Alonso-Orduna V, Schlichting C, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14: 29-37.
-
(2013)
Lancet Oncol
, vol.14
, pp. 29-37
-
-
Bennouna, J.1
Sastre, J.2
Arnold, D.3
Osterlund, P.4
Greil, R.5
Van Cutsem, E.6
von Moos, R.7
Vieitez, J.M.8
Bouche, O.9
Borg, C.10
Steffens, C.C.11
Alonso-Orduna, V.12
Schlichting, C.13
-
23
-
-
84926476833
-
Continuation or reintroduction of bevacizumab beyond progression to firstline therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
-
Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, Granetto C, Fea E, Antonuzzo L, et al. Continuation or reintroduction of bevacizumab beyond progression to firstline therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol. 2015; 26: 724-730.
-
(2015)
Ann Oncol
, vol.26
, pp. 724-730
-
-
Masi, G.1
Salvatore, L.2
Boni, L.3
Loupakis, F.4
Cremolini, C.5
Fornaro, L.6
Schirripa, M.7
Cupini, S.8
Barbara, C.9
Safina, V.10
Granetto, C.11
Fea, E.12
Antonuzzo, L.13
-
24
-
-
84875998274
-
Markers of response for the antiangiogenic agent bevacizumab
-
Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013; 31: 1219-1230.
-
(2013)
J Clin Oncol
, vol.31
, pp. 1219-1230
-
-
Lambrechts, D.1
Lenz, H.J.2
de Haas, S.3
Carmeliet, P.4
Scherer, S.J.5
-
25
-
-
0022298591
-
Proposal for using a standardized terminology on oxygen transport to tissue
-
Zander R, Vaupel P. Proposal for using a standardized terminology on oxygen transport to tissue. Adv Exp Med Biol. 1985; 191: 965-970.
-
(1985)
Adv Exp Med Biol
, vol.191
, pp. 965-970
-
-
Zander, R.1
Vaupel, P.2
-
26
-
-
84923673640
-
The role of hypoxia in inflammatory disease (Review)
-
Biddlestone J, Bandarra D, Rocha S. The role of hypoxia in inflammatory disease (Review). Int J Mol Med. 2015; 35: 859-869.
-
(2015)
Int J Mol Med
, vol.35
, pp. 859-869
-
-
Biddlestone, J.1
Bandarra, D.2
Rocha, S.3
-
27
-
-
0035925098
-
Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects
-
Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001; 93: 266-276.
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 266-276
-
-
Hockel, M.1
Vaupel, P.2
-
28
-
-
0034989311
-
Biological consequences of tumor hypoxia
-
Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Sem Oncol. 2001; 28: 36-41.
-
(2001)
Sem Oncol
, vol.28
, pp. 36-41
-
-
Hockel, M.1
Vaupel, P.2
-
30
-
-
0029051439
-
Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension
-
Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92: 5510-5514.
-
(1995)
Proc Natl Acad Sci U S A
, vol.92
, pp. 5510-5514
-
-
Wang, G.L.1
Jiang, B.H.2
Rue, E.A.3
Semenza, G.L.4
-
31
-
-
0035917313
-
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing
-
Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG,Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001; 292: 464-468.
-
(2001)
Science
, vol.292
, pp. 464-468
-
-
Ivan, M.1
Kondo, K.2
Yang, H.3
Kim, W.4
Valiando, J.5
Ohh, M.6
Salic, A.7
Asara, J.M.8
Lane, W.S.9
Kaelin, W.G.10
-
32
-
-
0035917808
-
Targeting of HIF-alpha to the von HippelLindau ubiquitylation complex by O2-regulated prolyl hydroxylation
-
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von HippelLindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292: 468-472.
-
(2001)
Science
, vol.292
, pp. 468-472
-
-
Jaakkola, P.1
Mole, D.R.2
Tian, Y.M.3
Wilson, M.I.4
Gielbert, J.5
Gaskell, S.J.6
von Kriegsheim, A.7
Hebestreit, H.F.8
Mukherji, M.9
Schofield, C.J.10
Maxwell, P.H.11
Pugh, C.W.12
Ratcliffe, P.J.13
-
33
-
-
0025885693
-
Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene
-
Pugh CW, Tan CC, Jones RW, Ratcliffe PJ. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. Proc Natl Acad Sci U S A. 1991; 88: 10553-10557.
-
(1991)
Proc Natl Acad Sci U S A
, vol.88
, pp. 10553-10557
-
-
Pugh, C.W.1
Tan, C.C.2
Jones, R.W.3
Ratcliffe, P.J.4
-
34
-
-
0030460724
-
Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1
-
Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996; 271: 32529-32537.
-
(1996)
J Biol Chem
, vol.271
, pp. 32529-32537
-
-
Semenza, G.L.1
Jiang, B.H.2
Leung, S.W.3
Passantino, R.4
Concordet, J.P.5
Maire, P.6
Giallongo, A.7
-
35
-
-
60549083256
-
Regulation of cancer cell metabolism by hypoxia-inducible factor 1
-
Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Sem Cancer Biol. 2009; 19: 12-16.
-
(2009)
Sem Cancer Biol
, vol.19
, pp. 12-16
-
-
Semenza, G.L.1
-
36
-
-
84867514301
-
Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy
-
Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012; 18: 5585-5594.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 5585-5594
-
-
Meijer, T.W.1
Kaanders, J.H.2
Span, P.N.3
Bussink, J.4
-
37
-
-
68749098573
-
Vascular reactions of normal and malignant tissues in vivo. III. Vascular reactions' of mice to fibroblasts treated in vitro with methylcholanthrene
-
Algire GH, Chalkley HW, Earle WE, Legallais FY, Park HD, Shelton E, Schilling El. Vascular reactions of normal and malignant tissues in vivo. III. Vascular reactions' of mice to fibroblasts treated in vitro with methylcholanthrene. J Natl Cancer Inst. 1950; 11: 555-580.
-
(1950)
J Natl Cancer Inst
, vol.11
, pp. 555-580
-
-
Algire, G.H.1
Chalkley, H.W.2
Earle, W.E.3
Legallais, F.Y.4
Park, H.D.5
Shelton, E.6
Schilling, E.L.7
-
38
-
-
0023157363
-
Angiogenic factors
-
Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987; 235: 442-447.
-
(1987)
Science
, vol.235
, pp. 442-447
-
-
Folkman, J.1
Klagsbrun, M.2
-
39
-
-
0031035987
-
Angiogenesis in colorectal cancer
-
Saclarides TJ. Angiogenesis in colorectal cancer. Surg Clin North Am. 1997; 77: 253-260.
-
(1997)
Surg Clin North Am
, vol.77
, pp. 253-260
-
-
Saclarides, T.J.1
-
40
-
-
0842333731
-
The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion
-
Takahashi Y, Ellis LM, Mai M. The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion. Oncol Rep. 2003; 10: 9-13.
-
(2003)
Oncol Rep
, vol.10
, pp. 9-13
-
-
Takahashi, Y.1
Ellis, L.M.2
Mai, M.3
-
41
-
-
84921679225
-
Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept
-
Giordano G, Febbraro A, Venditti M, Campidoglio S, Olivieri N, Raieta K, Parcesepe P, Imbriani GC, Remo A, Pancione M. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterol Res Pract. 2014; 2014: 526178.
-
(2014)
Gastroenterol Res Pract
, vol.2014
-
-
Giordano, G.1
Febbraro, A.2
Venditti, M.3
Campidoglio, S.4
Olivieri, N.5
Raieta, K.6
Parcesepe, P.7
Imbriani, G.C.8
Remo, A.9
Pancione, M.10
-
42
-
-
85013312416
-
Tumor angiogenesis: therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-1186.
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
43
-
-
0037967272
-
Tumorigenesis and the angiogenic switch
-
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3: 401-410.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 401-410
-
-
Bergers, G.1
Benjamin, L.E.2
-
44
-
-
0029761644
-
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
-
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16: 4604-4613.
-
(1996)
Mol Cell Biol
, vol.16
, pp. 4604-4613
-
-
Forsythe, J.A.1
Jiang, B.H.2
Iyer, N.V.3
Agani, F.4
Leung, S.W.5
Koos, R.D.6
Semenza, G.L.7
-
46
-
-
33751192872
-
Regulation of angiogenesis by hypoxia and hypoxia-inducible factors
-
Hickey MM, Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol. 2006; 76: 217-257.
-
(2006)
Curr Top Dev Biol
, vol.76
, pp. 217-257
-
-
Hickey, M.M.1
Simon, M.C.2
-
47
-
-
0036842215
-
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
-
Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002; 20: 4368-4380.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4368-4380
-
-
Dvorak, H.F.1
-
48
-
-
47949089077
-
VEGF-targeted therapy: mechanisms of anti-tumour activity
-
Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8: 579-591.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 579-591
-
-
Ellis, L.M.1
Hicklin, D.J.2
-
49
-
-
0030026897
-
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
-
Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996; 15: 290-298.
-
(1996)
EMBO J
, vol.15
, pp. 290-298
-
-
Joukov, V.1
Pajusola, K.2
Kaipainen, A.3
Chilov, D.4
Lahtinen, I.5
Kukk, E.6
Saksela, O.7
Kalkkinen, N.8
Alitalo, K.9
-
50
-
-
0032549799
-
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
-
Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92: 735-745.
-
(1998)
Cell
, vol.92
, pp. 735-745
-
-
Soker, S.1
Takashima, S.2
Miao, H.Q.3
Neufeld, G.4
Klagsbrun, M.5
-
51
-
-
0037699954
-
The biology of VEGF and its receptors
-
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669-676.
-
(2003)
Nat Med
, vol.9
, pp. 669-676
-
-
Ferrara, N.1
Gerber, H.P.2
LeCouter, J.3
-
52
-
-
0033118228
-
VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells
-
Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999; 18: 2221-2230.
-
(1999)
Oncogene
, vol.18
, pp. 2221-2230
-
-
Takahashi, T.1
Ueno, H.2
Shibuya, M.3
-
53
-
-
0035966004
-
Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation
-
Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem. 2001; 276: 49289-49298.
-
(2001)
J Biol Chem
, vol.276
, pp. 49289-49298
-
-
Meadows, K.N.1
Bryant, P.2
Pumiglia, K.3
-
54
-
-
0141838134
-
Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids
-
Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, Mercurio AM. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol. 2003; 13: 1721-1727.
-
(2003)
Curr Biol
, vol.13
, pp. 1721-1727
-
-
Bates, R.C.1
Goldsmith, J.D.2
Bachelder, R.E.3
Brown, C.4
Shibuya, M.5
Oettgen, P.6
Mercurio, A.M.7
-
55
-
-
21144437844
-
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels
-
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005; 65: 4739-4746.
-
(2005)
Cancer Res
, vol.65
, pp. 4739-4746
-
-
He, Y.1
Rajantie, I.2
Pajusola, K.3
Jeltsch, M.4
Holopainen, T.5
Yla-Herttuala, S.6
Harding, T.7
Jooss, K.8
Takahashi, T.9
Alitalo, K.10
-
56
-
-
0037093078
-
Placental growth factor is a survival factor for tumor endothelial cells and macrophages
-
Adini A, Kornaga T, Firoozbakht F, Benjamin LE. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res. 2002; 62: 2749-2752.
-
(2002)
Cancer Res
, vol.62
, pp. 2749-2752
-
-
Adini, A.1
Kornaga, T.2
Firoozbakht, F.3
Benjamin, L.E.4
-
57
-
-
84867235528
-
Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
-
63-8722-5-63
-
Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol. 2012; 5: 63-8722-5-63.
-
(2012)
J Hematol Oncol
, vol.5
-
-
Sun, W.1
-
58
-
-
0033677954
-
Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer
-
Kuniyasu H, Yasui W, Shinohara H, Yano S, Ellis LM, Wilson MR, Bucana CD, Rikita T, Tahara E, Fidler IJ. Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. Am J Pathol. 2000; 157: 1523-1535.
-
(2000)
Am J Pathol
, vol.157
, pp. 1523-1535
-
-
Kuniyasu, H.1
Yasui, W.2
Shinohara, H.3
Yano, S.4
Ellis, L.M.5
Wilson, M.R.6
Bucana, C.D.7
Rikita, T.8
Tahara, E.9
Fidler, I.J.10
-
59
-
-
33745102388
-
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
-
Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006; 94: 1823-1832.
-
(2006)
Br J Cancer
, vol.94
, pp. 1823-1832
-
-
Des Guetz, G.1
Uzzan, B.2
Nicolas, P.3
Cucherat, M.4
Morere, J.F.5
Benamouzig, R.6
Breau, J.L.7
Perret, G.Y.8
-
60
-
-
67650753834
-
The role of the Angiopoietins in vascular morphogenesis
-
Thomas M, Augustin HG. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis. 2009; 12: 125-137.
-
(2009)
Angiogenesis
, vol.12
, pp. 125-137
-
-
Thomas, M.1
Augustin, H.G.2
-
61
-
-
54549089738
-
Hypoxia signalling through mTOR and the unfolded protein response in cancer
-
Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008; 8: 851-864.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 851-864
-
-
Wouters, B.G.1
Koritzinsky, M.2
-
62
-
-
28844470269
-
The unfolded protein response: a novel component of the hypoxic stress response in tumors
-
Feldman DE, Chauhan V, Koong AC. The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res. 2005; 3: 597-605.
-
(2005)
Mol Cancer Res
, vol.3
, pp. 597-605
-
-
Feldman, D.E.1
Chauhan, V.2
Koong, A.C.3
-
63
-
-
33746886623
-
"Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPRindependent pathways
-
Koumenis C, Wouters BG. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPRindependent pathways. Mol Cancer Res. 2006; 4: 423-436.
-
(2006)
Mol Cancer Res
, vol.4
, pp. 423-436
-
-
Koumenis, C.1
Wouters, B.G.2
-
64
-
-
67349119514
-
Regulation of angiogenesis by oxygen sensing mechanisms
-
Fong GH. Regulation of angiogenesis by oxygen sensing mechanisms. J Mol Med. 2009; 87: 549-560.
-
(2009)
J Mol Med
, vol.87
, pp. 549-560
-
-
Fong, G.H.1
-
65
-
-
0029551759
-
Microvascular corrosion casting in the study of tumor vascularity: a review
-
discussion 1243-1244
-
Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scan Micr. 1995; 9: 1233-1243; discussion 1243-1244.
-
(1995)
Scan Micr
, vol.9
, pp. 1233-1243
-
-
Konerding, M.A.1
Miodonski, A.J.2
Lametschwandtner, A.3
-
66
-
-
84912096468
-
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia
-
Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014; 26: 605-622.
-
(2014)
Cancer Cell
, vol.26
, pp. 605-622
-
-
Jain, R.K.1
-
67
-
-
84874886049
-
Acidity generated by the tumor microenvironment drives local invasion
-
Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, Bailey K, Balagurunathan Y, Rothberg JM, Sloane BF, Johnson J, Gatenby RA, Gillies RJ. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013; 73: 1524-1535.
-
(2013)
Cancer Res
, vol.73
, pp. 1524-1535
-
-
Estrella, V.1
Chen, T.2
Lloyd, M.3
Wojtkowiak, J.4
Cornnell, H.H.5
Ibrahim-Hashim, A.6
Bailey, K.7
Balagurunathan, Y.8
Rothberg, J.M.9
Sloane, B.F.10
Johnson, J.11
Gatenby, R.A.12
Gillies, R.J.13
-
68
-
-
77951228314
-
The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy
-
DeClerck K, Elble RC. The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci. 2010; 15: 213-225.
-
(2010)
Front Biosci
, vol.15
, pp. 213-225
-
-
DeClerck, K.1
Elble, R.C.2
-
69
-
-
0035432151
-
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review)
-
Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol. 2001; 19: 257-262.
-
(2001)
Int J Oncol
, vol.19
, pp. 257-262
-
-
Blagosklonny, M.V.1
-
70
-
-
1642472018
-
Antiangiogenic therapy and tumor progression
-
Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004; 5: 13-17.
-
(2004)
Cancer Cell
, vol.5
, pp. 13-17
-
-
Blagosklonny, M.V.1
-
71
-
-
84922977686
-
Regulatory role of glycans in the control of hypoxiadriven angiogenesis and sensitivity to anti-angiogenic treatment
-
Croci DO, Cerliani JP, Pinto NA, Morosi LG, Rabinovich GA. Regulatory role of glycans in the control of hypoxiadriven angiogenesis and sensitivity to anti-angiogenic treatment. Glycobiology. 2014; 24: 1283-1290.
-
(2014)
Glycobiology
, vol.24
, pp. 1283-1290
-
-
Croci, D.O.1
Cerliani, J.P.2
Pinto, N.A.3
Morosi, L.G.4
Rabinovich, G.A.5
-
72
-
-
84893639632
-
Acidic priming enhances metastatic potential of cancer cells
-
Riemann A, Schneider B, Gundel D, Stock C, Thews O, Gekle M. Acidic priming enhances metastatic potential of cancer cells. Eur J Physiol. 2014; 466: 2127-2138.
-
(2014)
Eur J Physiol
, vol.466
, pp. 2127-2138
-
-
Riemann, A.1
Schneider, B.2
Gundel, D.3
Stock, C.4
Thews, O.5
Gekle, M.6
-
73
-
-
84914105725
-
Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy
-
Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Met Rev. 2014; 33: 1095-1108.
-
(2014)
Cancer Met Rev
, vol.33
, pp. 1095-1108
-
-
Fais, S.1
Venturi, G.2
Gatenby, B.3
-
74
-
-
0037214282
-
Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia
-
Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol. 2003; 23: 359-369.
-
(2003)
Mol Cell Biol
, vol.23
, pp. 359-369
-
-
Goda, N.1
Ryan, H.E.2
Khadivi, B.3
McNulty, W.4
Rickert, R.C.5
Johnson, R.S.6
-
75
-
-
84899771418
-
Carbonic anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells
-
McDonald PC, Dedhar S. Carbonic anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells. Subcell Biochem. 2014; 75: 255-269.
-
(2014)
Subcell Biochem
, vol.75
, pp. 255-269
-
-
McDonald, P.C.1
Dedhar, S.2
-
76
-
-
79956196320
-
Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis
-
Ziech D, Franco R, Pappa A, Panayiotidis MI. Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res. 2011; 711: 167-173.
-
(2011)
Mutat Res
, vol.711
, pp. 167-173
-
-
Ziech, D.1
Franco, R.2
Pappa, A.3
Panayiotidis, M.I.4
-
77
-
-
84881232071
-
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
-
Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013; 123: 3190-3200.
-
(2013)
J Clin Invest
, vol.123
, pp. 3190-3200
-
-
Welti, J.1
Loges, S.2
Dimmeler, S.3
Carmeliet, P.4
-
78
-
-
84885578429
-
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice
-
Rovida A, Castiglioni V, Decio A, Scarlato V, Scanziani E, Giavazzi R, Cesca M. Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice. Mol Cancer Ther. 2013; 12: 2237-2247.
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 2237-2247
-
-
Rovida, A.1
Castiglioni, V.2
Decio, A.3
Scarlato, V.4
Scanziani, E.5
Giavazzi, R.6
Cesca, M.7
-
79
-
-
84897990135
-
Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment
-
Casazza A, Di Conza G, Wenes M, Finisguerra V, Deschoemaeker S, Mazzone M. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene. 2014; 33: 1743-1754.
-
(2014)
Oncogene
, vol.33
, pp. 1743-1754
-
-
Casazza, A.1
Di Conza, G.2
Wenes, M.3
Finisguerra, V.4
Deschoemaeker, S.5
Mazzone, M.6
-
80
-
-
84907223092
-
Functional polarization of tumour-associated macrophages by tumourderived lactic acid
-
Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, Cline GW, Phillips AJ, Medzhitov R. Functional polarization of tumour-associated macrophages by tumourderived lactic acid. Nature. 2014; 513: 559-563.
-
(2014)
Nature
, vol.513
, pp. 559-563
-
-
Colegio, O.R.1
Chu, N.Q.2
Szabo, A.L.3
Chu, T.4
Rhebergen, A.M.5
Jairam, V.6
Cyrus, N.7
Brokowski, C.E.8
Eisenbarth, S.C.9
Phillips, G.M.10
Cline, G.W.11
Phillips, A.J.12
Medzhitov, R.13
-
81
-
-
77954563464
-
Hypoxia, inflammation, and the tumor microenvironment in metastatic disease
-
Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Met Rev. 2010; 29: 285-293.
-
(2010)
Cancer Met Rev
, vol.29
, pp. 285-293
-
-
Finger, E.C.1
Giaccia, A.J.2
-
82
-
-
84858590826
-
Accessories to the crime: functions of cells recruited to the tumor microenvironment
-
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21: 309-322.
-
(2012)
Cancer Cell
, vol.21
, pp. 309-322
-
-
Hanahan, D.1
Coussens, L.M.2
-
83
-
-
84880757177
-
Deciphering and reversing tumor immune suppression
-
Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013; 39: 61-73.
-
(2013)
Immunity
, vol.39
, pp. 61-73
-
-
Motz, G.T.1
Coukos, G.2
-
84
-
-
84904406680
-
Tumor-associated macrophages: from mechanisms to therapy
-
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41: 49-61.
-
(2014)
Immunity
, vol.41
, pp. 49-61
-
-
Noy, R.1
Pollard, J.W.2
-
85
-
-
84857702419
-
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer
-
Palazon A, Aragones J, Morales-Kastresana A, de Landazuri MO, Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res. 2012; 18: 1207-1213.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1207-1213
-
-
Palazon, A.1
Aragones, J.2
Morales-Kastresana, A.3
de Landazuri, M.O.4
Melero, I.5
-
86
-
-
84899753178
-
PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
-
Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014; 211: 781-790.
-
(2014)
J Exp Med
, vol.211
, pp. 781-790
-
-
Noman, M.Z.1
Desantis, G.2
Janji, B.3
Hasmim, M.4
Karray, S.5
Dessen, P.6
Bronte, V.7
Chouaib, S.8
-
87
-
-
79957534572
-
Targeting hypoxia in cancer therapy
-
Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011; 11: 393-410.
-
(2011)
Nat Rev Cancer
, vol.11
, pp. 393-410
-
-
Wilson, W.R.1
Hay, M.P.2
-
88
-
-
60649087564
-
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
-
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer cell. 2009; 15: 232-239.
-
(2009)
Cancer cell
, vol.15
, pp. 232-239
-
-
Ebos, J.M.1
Lee, C.R.2
Cruz-Munoz, W.3
Bjarnason, G.A.4
Christensen, J.G.5
Kerbel, R.S.6
-
89
-
-
60649106195
-
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
-
Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer cell. 2009; 15: 220-231.
-
(2009)
Cancer cell
, vol.15
, pp. 220-231
-
-
Paez-Ribes, M.1
Allen, E.2
Hudock, J.3
Takeda, T.4
Okuyama, H.5
Vinals, F.6
Inoue, M.7
Bergers, G.8
Hanahan, D.9
Casanovas, O.10
-
90
-
-
84904987878
-
Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor
-
Mesange P, Poindessous V, Sabbah M, Escargueil AE, de Gramont A, Larsen AK. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget. 2014; 5: 4709-4721. doi: 10.18632/oncotarget.1671.
-
(2014)
Oncotarget
, vol.5
, pp. 4709-4721
-
-
Mesange, P.1
Poindessous, V.2
Sabbah, M.3
Escargueil, A.E.4
de Gramont, A.5
Larsen, A.K.6
-
91
-
-
84947748945
-
Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways
-
Greening DW, Lee ST, Ji H, Simpson RJ, Rigopoulos A, Murone C, Fang C, Gong S, O'Keefe G, Scott AM. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. Oncotarget. 2015; 6: 38166-38180. doi: 10.18632/oncotarget.6241.
-
(2015)
Oncotarget
, vol.6
, pp. 38166-38180
-
-
Greening, D.W.1
Lee, S.T.2
Ji, H.3
Simpson, R.J.4
Rigopoulos, A.5
Murone, C.6
Fang, C.7
Gong, S.8
O'Keefe, G.9
Scott, A.M.10
-
92
-
-
84857630253
-
Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab
-
Weisshardt P, Trarbach T, Durig J, Paul A, Reis H, Tilki D, Miroschnik I, Ergun S, Klein D. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol. 2012; 137: 391-401.
-
(2012)
Histochem Cell Biol
, vol.137
, pp. 391-401
-
-
Weisshardt, P.1
Trarbach, T.2
Durig, J.3
Paul, A.4
Reis, H.5
Tilki, D.6
Miroschnik, I.7
Ergun, S.8
Klein, D.9
-
93
-
-
84855167770
-
Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles
-
Mehta S, Hughes NP, Buffa FM, Li SP, Adams RF, Adwani A, Taylor NJ, Levitt NC, Padhani AR, Makris A, Harris AL. Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. J Natl Cancer Inst. 2011; 2011: 71-74.
-
(2011)
J Natl Cancer Inst
, vol.2011
, pp. 71-74
-
-
Mehta, S.1
Hughes, N.P.2
Buffa, F.M.3
Li, S.P.4
Adams, R.F.5
Adwani, A.6
Taylor, N.J.7
Levitt, N.C.8
Padhani, A.R.9
Makris, A.10
Harris, A.L.11
-
94
-
-
84855931910
-
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs
-
Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serne EH, Lammertsma AA, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell. 2012; 21: 82-91.
-
(2012)
Cancer Cell
, vol.21
, pp. 82-91
-
-
Van der Veldt, A.A.1
Lubberink, M.2
Bahce, I.3
Walraven, M.4
de Boer, M.P.5
Greuter, H.N.6
Hendrikse, N.H.7
Eriksson, J.8
Windhorst, A.D.9
Postmus, P.E.10
Verheul, H.M.11
Serne, E.H.12
Lammertsma, A.A.13
-
95
-
-
84887419886
-
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
-
Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013; 110: 19059-19064.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 19059-19064
-
-
Batchelor, T.T.1
Gerstner, E.R.2
Emblem, K.E.3
Duda, D.G.4
Kalpathy-Cramer, J.5
Snuderl, M.6
Ancukiewicz, M.7
Polaskova, P.8
Pinho, M.C.9
Jennings, D.10
Plotkin, S.R.11
Chi, A.S.12
Eichler, A.F.13
-
96
-
-
84856302564
-
Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study
-
Hattingen E, Jurcoane A, Bahr O, Rieger J, Magerkurth J, Anti S, Steinbach JP, Pilatus U. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol. 2011; 13: 1349-1363.
-
(2011)
Neuro Oncol
, vol.13
, pp. 1349-1363
-
-
Hattingen, E.1
Jurcoane, A.2
Bahr, O.3
Rieger, J.4
Magerkurth, J.5
Anti, S.6
Steinbach, J.P.7
Pilatus, U.8
-
97
-
-
11144354392
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
-
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10: 145-147.
-
(2004)
Nat Med
, vol.10
, pp. 145-147
-
-
Willett, C.G.1
Boucher, Y.2
di Tomaso, E.3
Duda, D.G.4
Munn, L.L.5
Tong, R.T.6
Chung, D.C.7
Sahani, D.V.8
Kalva, S.P.9
Kozin, S.V.10
Mino, M.11
Cohen, K.S.12
Scadden, D.T.13
-
98
-
-
80051544936
-
Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response
-
Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, Gonen M, Bamboat Z, Shia J, Haviland D, D'Angelica MI, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol. 2011; 18: 2192-2199.
-
(2011)
Ann Surg Oncol
, vol.18
, pp. 2192-2199
-
-
Yopp, A.C.1
Schwartz, L.H.2
Kemeny, N.3
Gultekin, D.H.4
Gonen, M.5
Bamboat, Z.6
Shia, J.7
Haviland, D.8
D'Angelica, M.I.9
Fong, Y.10
DeMatteo, R.P.11
Allen, P.J.12
Jarnagin, W.R.13
-
99
-
-
84861145421
-
Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy
-
DeLay M, Jahangiri A, Carbonell WS, Hu YL, Tsao S, Tom MW, Paquette J, Tokuyasu TA, Aghi MK. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res. 2012; 18: 2930-2942.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2930-2942
-
-
DeLay, M.1
Jahangiri, A.2
Carbonell, W.S.3
Hu, Y.L.4
Tsao, S.5
Tom, M.W.6
Paquette, J.7
Tokuyasu, T.A.8
Aghi, M.K.9
-
100
-
-
84938770819
-
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial
-
258-015-0619-5
-
Ulivi P, Scarpi E, Passardi A, Marisi G, Calistri D, Zoli W, Del Re M, Frassineti GL, Tassinari D, Tamberi S, Vertogen B, Amadori D. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. J Transl Med. 2015; 13: 258-015-0619-5.
-
(2015)
J Transl Med
, vol.13
-
-
Ulivi, P.1
Scarpi, E.2
Passardi, A.3
Marisi, G.4
Calistri, D.5
Zoli, W.6
Del Re, M.7
Frassineti, G.L.8
Tassinari, D.9
Tamberi, S.10
Vertogen, B.11
Amadori, D.12
-
101
-
-
84862907876
-
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion
-
Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012; 72: 402-407.
-
(2012)
Cancer Res
, vol.72
, pp. 402-407
-
-
Sorensen, A.G.1
Emblem, K.E.2
Polaskova, P.3
Jennings, D.4
Kim, H.5
Ancukiewicz, M.6
Wang, M.7
Wen, P.Y.8
Ivy, P.9
Batchelor, T.T.10
Jain, R.K.11
-
103
-
-
0036359548
-
Hypoxia-a key regulatory factor in tumour growth
-
Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2: 38-47.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 38-47
-
-
Harris, A.L.1
-
104
-
-
37649019157
-
Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients
-
Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, Sherod A, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV, Lenz HJ. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics. 2007; 8: 1705-1713.
-
(2007)
Pharmacogenomics
, vol.8
, pp. 1705-1713
-
-
Azuma, M.1
Shi, M.2
Danenberg, K.D.3
Gardner, H.4
Barrett, C.5
Jacques, C.J.6
Sherod, A.7
Iqbal, S.8
El-Khoueiry, A.9
Yang, D.10
Zhang, W.11
Danenberg, P.V.12
Lenz, H.J.13
-
105
-
-
0034909448
-
Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer
-
Tas F, Aydiner A, Demir C, Topuz E. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol. 2001; 24: 376-378.
-
(2001)
Am J Clin Oncol
, vol.24
, pp. 376-378
-
-
Tas, F.1
Aydiner, A.2
Demir, C.3
Topuz, E.4
-
106
-
-
0035205830
-
Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease
-
Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol. 2001; 24: 547-550.
-
(2001)
Am J Clin Oncol
, vol.24
, pp. 547-550
-
-
Tas, F.1
Aykan, F.2
Alici, S.3
Kaytan, E.4
Aydiner, A.5
Topuz, E.6
-
107
-
-
84857790397
-
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
-
Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, Galizia E, Loretelli C, Belvederesi L, Bittoni A, Cascinu S. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 2012; 106: 799-804.
-
(2012)
Br J Cancer
, vol.106
, pp. 799-804
-
-
Scartozzi, M.1
Giampieri, R.2
Maccaroni, E.3
Del Prete, M.4
Faloppi, L.5
Bianconi, M.6
Galizia, E.7
Loretelli, C.8
Belvederesi, L.9
Bittoni, A.10
Cascinu, S.11
-
108
-
-
84907376447
-
Initial LDH level can predict the survival benefit from bevacizumab in the firstline setting in Chinese patients with metastatic colorectal cancer
-
Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L. Initial LDH level can predict the survival benefit from bevacizumab in the firstline setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2014; 7: 1415-1422.
-
(2014)
Onco Targets Ther
, vol.7
, pp. 1415-1422
-
-
Yin, C.1
Jiang, C.2
Liao, F.3
Rong, Y.4
Cai, X.5
Guo, G.6
Qiu, H.7
Chen, X.8
Zhang, B.9
He, W.10
Xia, L.11
-
109
-
-
84941955861
-
Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
-
Passardi A, Scarpi E, Tamberi S, Cavanna L, Tassinari D, Fontana A, Pini S, Bernardini I, Accettura C, Ulivi P, Frassineti GL, Amadori D. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. PloS One. 2015; 10: e0134732.
-
(2015)
PloS One
, vol.10
-
-
Passardi, A.1
Scarpi, E.2
Tamberi, S.3
Cavanna, L.4
Tassinari, D.5
Fontana, A.6
Pini, S.7
Bernardini, I.8
Accettura, C.9
Ulivi, P.10
Frassineti, G.L.11
Amadori, D.12
-
110
-
-
84895073003
-
Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study
-
Bar J, Spencer S, Morgan S, Brooks L, Cunningham D, Robertson J, Jurgensmeier JM, Goss GD. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study. Clin Colorectal Cancer. 2014; 13: 46-53.
-
(2014)
Clin Colorectal Cancer
, vol.13
, pp. 46-53
-
-
Bar, J.1
Spencer, S.2
Morgan, S.3
Brooks, L.4
Cunningham, D.5
Robertson, J.6
Jurgensmeier, J.M.7
Goss, G.D.8
-
111
-
-
84979949771
-
HIF-1 alpha expression as a predictor of bevacizumab efficacy in metastatic colorectal cancer
-
January 20 Supplement
-
Marisi G, Ulivi P, Scarpi E, Passardi A, Frassineti GL, Valgiusti M, Zoli W, Amadori D. HIF-1 alpha expression as a predictor of bevacizumab efficacy in metastatic colorectal cancer. J Clin Oncol. 2015; 33 No 3_suppl (January 20 Supplement): 601.
-
(2015)
J Clin Oncol
, vol.33
, Issue.3
, pp. 601
-
-
Marisi, G.1
Ulivi, P.2
Scarpi, E.3
Passardi, A.4
Frassineti, G.L.5
Valgiusti, M.6
Zoli, W.7
Amadori, D.8
-
112
-
-
84857022444
-
In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1alpha target genes and decreases tumor angiogenesis
-
Guerin E, Raffelsberger W, Pencreach E, Maier A, Neuville A, Schneider A, Bachellier P, Rohr S, Petitprez A, Poch O, Moras D, Oudet P, Larsen AK, et al. In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1alpha target genes and decreases tumor angiogenesis. Mol Med. 2012; 18: 83-94.
-
(2012)
Mol Med
, vol.18
, pp. 83-94
-
-
Guerin, E.1
Raffelsberger, W.2
Pencreach, E.3
Maier, A.4
Neuville, A.5
Schneider, A.6
Bachellier, P.7
Rohr, S.8
Petitprez, A.9
Poch, O.10
Moras, D.11
Oudet, P.12
Larsen, A.K.13
-
113
-
-
84896394473
-
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors
-
Jeong W, Park SR, Rapisarda A, Fer N, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. Invest New Drugs. 2014; 32: 340-346.
-
(2014)
Invest New Drugs
, vol.32
, pp. 340-346
-
-
Jeong, W.1
Park, S.R.2
Rapisarda, A.3
Fer, N.4
Kinders, R.J.5
Chen, A.6
Melillo, G.7
Turkbey, B.8
Steinberg, S.M.9
Choyke, P.10
Doroshow, J.H.11
Kummar, S.12
-
114
-
-
1242271198
-
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications
-
Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004; 64: 1475-1482.
-
(2004)
Cancer Res
, vol.64
, pp. 1475-1482
-
-
Rapisarda, A.1
Uranchimeg, B.2
Sordet, O.3
Pommier, Y.4
Shoemaker, R.H.5
Melillo, G.6
-
115
-
-
67651166780
-
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
-
Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009; 8: 1867-1877.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1867-1877
-
-
Rapisarda, A.1
Hollingshead, M.2
Uranchimeg, B.3
Bonomi, C.A.4
Borgel, S.D.5
Carter, J.P.6
Gehrs, B.7
Raffeld, M.8
Kinders, R.J.9
Parchment, R.10
Anver, M.R.11
Shoemaker, R.H.12
Melillo, G.13
-
116
-
-
84916912453
-
Targeting hypoxia-inducible factor-1alpha (HIF-1alpha) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
-
Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, et al. Targeting hypoxia-inducible factor-1alpha (HIF-1alpha) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014; 5: 10280-10292 doi: 10.18632/oncotarget.2163.
-
(2014)
Oncotarget
, vol.5
, pp. 10280-10292
-
-
Falchook, G.S.1
Wheler, J.J.2
Naing, A.3
Jackson, E.F.4
Janku, F.5
Hong, D.6
Ng, C.S.7
Tannir, N.M.8
Lawhorn, K.N.9
Huang, M.10
Angelo, L.S.11
Vishwamitra, D.12
Hess, K.13
-
117
-
-
84894523716
-
Making new contacts: the mTOR network in metabolism and signalling crosstalk
-
Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Biol. 2014; 15: 155-162.
-
(2014)
Nat Rev Mol Biol
, vol.15
, pp. 155-162
-
-
Shimobayashi, M.1
Hall, M.N.2
-
118
-
-
84863786833
-
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
-
Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol. 2012; 69: 1487-1498.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, pp. 1487-1498
-
-
Liu, Q.1
Sun, J.D.2
Wang, J.3
Ahluwalia, D.4
Baker, A.F.5
Cranmer, L.D.6
Ferraro, D.7
Wang, Y.8
Duan, J.X.9
Ammons, W.S.10
Curd, J.G.11
Matteucci, M.D.12
Hart, C.P.13
-
119
-
-
84958963072
-
Salternamide A Suppresses Hypoxia-Induced Accumulation of HIF-1alpha and Induces Apoptosis in Human Colorectal Cancer Cells
-
Bach DH, Kim SH, Hong JY, Park HJ, Oh DC, Lee SK. Salternamide A Suppresses Hypoxia-Induced Accumulation of HIF-1alpha and Induces Apoptosis in Human Colorectal Cancer Cells. Mar Drugs. 2015; 13: 6962-6976.
-
(2015)
Mar Drugs
, vol.13
, pp. 6962-6976
-
-
Bach, D.H.1
Kim, S.H.2
Hong, J.Y.3
Park, H.J.4
Oh, D.C.5
Lee, S.K.6
-
120
-
-
31144458716
-
How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy
-
Blagosklonny MV. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther. 2005; 4: 1307-1310.
-
(2005)
Cancer Biol Ther
, vol.4
, pp. 1307-1310
-
-
Blagosklonny, M.V.1
|